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granule-associated pruritogenic media-
tor from mast cells, histamine, were
markedly inhibited by PAC-14028,
whereas those by serotonin or throm-
boxane analog, U-46619, were not
affected. Partial attenuation of hista-
mine-mediated itch response might re-
flect the partial agonistic effect of
histamine on TRPV1 activation (Shim
et al., 2007), and the lack of antipruritic
efficacy on the scratching behaviors
evoked by serotonin or U-46619 was
anticipated as these pruritogens work
through G-protein-coupled receptors,
including 5-HT receptors and TP recep-
tor (Andoh et al., 2007; Imamachi et al.,
2009), that have little cross talk with
TRPV1-mediated pathways. Partial inhi-
bition of PAC-14028 on compound 48/
80-evoked itch may be explained by the
presence of TRPV1-independent itch
signals from serotonin or other prurito-
genic mediators in mast cell granules,
despite histamine- and tryptase-mediated
(PAR-2 mediated) itch responses could
be suppressed by TRPV1 blockade.
In conclusion, we found that TRPV1
antagonist, PAC-14028, can suppress
scratching behaviors associated with
AD-like symptoms through the inhibition
of TRPV1 activation, of which expression
and phosphorylation increase in AD-like
skin lesion. Particularly, experiments
with diverse pruritogens revealed that
PAC-14028 could manifest antipruritic
effects on TRPV1-, PAR-2-, and hista-
mine-mediated scratching behaviors.
Considering the frequent failure of
conventional antipruritic therapy (i.e.,
antihistamines) in the management of
severe itch symptoms, we believe that
TRPV1 antagonists can be a novel anti-
pruritic therapy that might satisfy the
unmet medical need.
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TO THE EDITOR
BRAF kinase has been found to be
mutationally activated in up to 70% of
benign nevi and melanomas (Davies
et al., 2002). It has been implicated as a
critical mediator of melanoma devel-
opment, with the V600E-activating mu-
tation representing the most commonly
mutated form of BRAF in nevi and
melanomas (Pollock et al., 2003).
Despite strong evidence implicating
BRAF kinase as a bona-fide oncogene
Abbreviations: EGFR, epidermal growth factor receptor; HPM, human primary melanocyte; MMP-1,
matrix metalloproteinase-1; siRNA, small interfering RNA
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in melanoma, its precise downstream
targets in melanocytes have not been
defined to date, and a BRAF-specific
gene signature in melanomas remains
uncertain (Hoek et al., 2006).
We have introduced activated
BRAFV600E into human primary melano-
cytes (HPMs) in order to assess its specific
functions (Figure 1a, Supplementary
Figure S2 online; also see Supplementary
information for details of experimental
methods). The gene expression signature
of HPMs induced by acute expression of
the BRAFV600E was assessed in compar-
ison with HPMs expressing green fluor-
escent protein (Figure 1c). The complete
dataset is accessible as GSE13827
(http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE13827). We found that
the BRAFV600E signature of HPMs was
characterized by upregulation of sev-
eral growth-promoting genes and
cellular motility and inflammation-
associated genes (Figure 1b) with a
common network activation of cellular
growth/proliferation and apoptosis
(Supplementary Figure S1 online). This
finding suggests that BRAFV600E may
induce gene signatures of biphasic
cellular responses, proliferation as
observed in melanomas, and onco-
gene-induced growth arrest as observed
in nevi. Detection of genes involved in
proliferation, such as MMP1, AREG,
CXCL5, IL-8, and EREG (Figure 1c and
Supplementary Table S1 online), im-
plies that the short-term cellular re-
sponse by acute BRAFV600E expression
may be HPM proliferation rather than
growth arrest, which appears to be a
long-term sustained effect of BRAFV600E
(Woods et al., 1997; Michaloglou et al.,
2005). Therefore, we reasoned that the
cellular proliferation signal induced by
the BRAFV600E in HPMs may be reacti-
vated in melanoma for tumor growth. In
order to test this hypothesis, we sought
to further examine the functional roles
of matrix metalloproteinase-1 (MMP-1)
as a BRAF effector in melanoma be-
cause MMP-1 is most strongly induced
by BRAF (Supplementary Table S1 on-
line) and is reported to be involved in
melanoma progression and metastasis
(Blackburn et al., 2007).
In order to determine whether
MMP-1 expression is correlated with
BRAFV600E expression in melanomas,
melanoma cell lines and HPMs were
examined for MMP-1 messenger RNA
expression using gene expression pro-
filing as previously described (Ryu
et al., 2007). We identified 25-fold
increased expression of MMP-1 mes-
senger RNA in melanoma cells posses-
sing BRAFV600E compared with wild
type whereas HPMs expressed similar
transcript levels with BRAF wild-type
melanoma cell (Figure 2a), suggesting
that increased BRAF kinase activity may
be associated with elevated MMP-1
expression in melanomas. We also
found that melanocytes expressing
BRAFV600E have increased levels of
secreted MMP-1 protein (Figure 2b)
and collagenase activity (Figure 2c)
versus HPM controls, suggesting that
the activated BRAF can induce both
MMP-1 protein expression and activity.
In order to determine the functional
significance of BRAF kinase induction
of MMP-1 in human melanomas, we
assessed the effect of MMP-1 gene
silencing on the proliferative functions
of BRAF kinase. MMP-1 messenger
RNA and protein levels were efficiently
reduced in melanomas possessing
either wild-type BRAF (WM852) or
mutant BRAFV600E (WM793) using tar-
geted MMP-1 small interfering RNA
(siRNA) (Figure 2d and e). Cellular
proliferation was assessed in both BRAF
wild-type and mutant melanomas fol-
lowing MMP-1 silencing by siRNA
(Figure 2f) and a neutralizing MMP-1
antibody (data not shown). Significant
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Figure 1. A proliferative gene signature induced by oncogenic BRAF in human primary melanocyte (HPM) and gene ontology (GO) annotation analysis.
(a) Activation of mitogen-activated protein kinase signal transduction pathway by acute expression of BRAFV600E in HPM. (b) A pie chart of the GO
annotation analysis. Eighty-two annotated genes from 137 probe sets that were identified as greater than threefold differentially expressed genes were
analyzed. P-value o0.005 was used for identification of the biological processes that may be regulated by BRAF downstream effectors. Numbers shown
in parentheses indicate number of genes classified as the suggested categories. (c) Heat map presentation of the downstream effector gene signature
induced by BRAFV600E. Top 15 up- and downregulated genes are shown. BRAFV600E; HPM expressing mutant BRAFV600E; GFP, HPM expressing
green fluorescent protein.
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inhibition of proliferation was seen in
both BRAF wild-type and mutant mel-
anoma cells following MMP-1 knock-
down; however, whereas cell growth
was inhibited only by 17% with MMP-1
siRNA versus control siRNA in BRAF
wild-type melanomas, growth inhibi-
tion by MMP-1 siRNA in the BRAF
mutant melanoma cells was signifi-
cantly more effective, at 80% inhibi-
tion, despite comparable gene silencing
(Figure 2f). We therefore conclude that
BRAFV600E may promote cellular
growth in melanomas through activated
expression of MMP-1. It should be
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Figure 2. Activated BRAF promotes melanoma cell growth by matrix metalloproteinase-1 (MMP-1). (a) Relative MMP-1 messenger RNA levels in human
primary melanocytes (HPMs) and melanoma cells expressing wild-type (WM852) or mutant BRAF (WM793). (b) Relative levels of secreted MMP-1 in
conditioned media obtained from HPMs expressing green fluorescent protein (GFP) or BRAFV600E at 72 h following lentiviral infection. (c) Relative MMP-1
collagenase activity in conditioned media obtained from HPMs expressing GFP or BRAFV600E at 72 h following lentiviral infection. (d) Quantitative real-time
RT-PCR (qRT-PCR) analysis of MMP-1 expression following gene silencing by small interfering (siRNA) in melanomas possessing either wild-type (WM852) or
mutant BRAFV600E (WM793). (e) Relative MMP-1 concentration in cell culture media following MMP-1 gene silencing in melanomas possessing wild-type
(WM852) and BRAFV600E (WM793) cells. (f) 3H-thymidine cell proliferation assay of melanomas possessing wild-type (WM852) and BRAFV600E (WM793)
following MMP-1 gene silencing. (g) Relative expression of activated amphiregulin (AREG) in conditioned media from HPMs expressing GFP or BRAFV600E.
(h) Relative expression of activated AREG in melanomas expressing wild-type (WM852) or mutant BRAF (WM793) following MMP-1 gene silencing.
Columns: mean of three individual experiments done in triplicate; bars, SD. *Po0.05, **Po0.01, ***Po0.001, compared with GFP control in b, c, g, and
compared with siRNA control (Scramble) in the d–f, h.
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noted that MMP-1 silencing by RNA
interference was previously shown to
affect only metastasis but not tumor
growth in a melanoma cell line
(VMM12) (Blackburn et al., 2007).
However, Blackburn et al. (2009) also
reported in a recent study that stable
overexpression of MMP-1 in Bowers
melanoma cells promotes xenograft
tumor growth. These data suggest vari-
able effects of MMP-1 in melanoma cell
lines, which are likely attributable to
the molecular heterogeneity of melano-
mas. It is likely that WM792 and
Bowers melanoma cells depend on
BRAF/MMP-1-mediated cellular path-
ways for tumor growth, which may not
be the case for VMM12 melanoma
cells. As we were able to show that
MMP-1 promotes growth in melanoma
cells expressing BRAFV600E, we sought
to clarify the functional targets for
MMP-1 in this setting. As amphiregulin
(AREG), a ligand for the epidermal
growth factor receptor (EGFR), was also
found to be significantly induced by
BRAFV600E in HPMs (Figure 1c and
Supplementary Table S1 online) and is
synthesized as a precursor protein that
is released from the plasma membrane
by metalloproteinases (Zhang et al.,
2004; Lu et al., 2009), we sought to
evaluate whether HPMs expressing
BRAFV600E expressed elevated levels of
activated AREG. We found 4100-fold
expression of activated AREG in HPMs
expressing BRAFV600E versus controls
(Figure 2g). In order to determine
whether induction of activated AREG
in HPMs expressing BRAFV600E was due
to cleavage by activated MMP-1, we
evaluated the effect of silencing MMP-1
on expression of activated AREG in
melanoma cells expressing BRAFV600E
versus wild-type BRAF-expressing mel-
anoma cells. We found that silencing of
MMP-1 led to a significant reduction in
levels of cleaved AREG in BRAFV600E
melanoma cells, but no signi-
ficant change in expression in the
BRAF wild-type melanoma cells
(Figure 2h).
Although previous studies suggested
that BRAF kinase activity promotes
expression of MMP-1 in melanoma
(Huntington et al., 2004) and that
MMP-1 promotes melanoma progres-
sion (Blackburn et al., 2007), these
authors conclude that induction of
MMP-1 in melanoma is specifically
important for melanoma progression
and metastasis through degradation
functions on interstitial collagens. Here
we show that MMP-1 is a critical
mediator of the growth-promoting func-
tions of BRAF kinase in melanoma
cells, which is consistent with a pro-
liferative role for BRAFV600E in the
development of melanomas. Indeed,
recent studies have suggested an addi-
tional important role for MMPs in
activating latent growth factors that
may be critical to the effects of MMP-1
seen in our studies. Notably, MMP-1
has been implicated in activating breast
cancer and melanoma cell growth
through proteolytic activation of the
cell surface receptor PAR1 (Boire et al.,
2005; Blackburn et al., 2009). Together
with the report that EGFR is highly
expressed in vertical-growth-phase pri-
mary (89%) and metastatic melanoma
(80%) (Rodeck et al., 1991), the data
presented in this study demonstrating
the growth-promoting function of
MMP-1 in human melanomas suggest
that BRAFV600E-induced activation of
an autocrine feedback loop (MMP-1/
AREG/EGFR/RAS/BRAF) may have a
critical role in melanoma growth and
metastasis. It is also possible that tumor
cell-induced AREG expression and ac-
tivation may affect the growth of
neighboring endothelial and stromal
cells. This may further promote tumor
cell metastasis by modulating the tu-
mor-specific microenvironment. Taken
together, this feedback loop could be
an important player for melanoma
progression and a molecular target for
melanoma therapy. Further studies are
currently ongoing to test this hypothesis
using EGFR inhibitors in our experi-
mental model.
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TO THE EDITOR
Seborrheic keratoses (SKs) are among
the most common benign tumors in
humans, occurring in 80–100% of people
over 50 years of age (Yeatman et al.,
1997; Kwon et al., 2003). Although not
life-threatening, SKs may become irri-
tated and itchy, are often unattractive and
disfiguring, and may have a significantly
negative psychological impact as daily
reminders of aging. Several recent studies
of the pathogenesis of SK have identi-
fied the importance of somatic activating
mutations of fibroblast growth factor
receptor 3 (FGFR3) (Logie et al., 2005;
Hafner et al., 2006a, b, 2007a, b, c)
and oncogenic mutations of the p110a
subunit (PIK3CA) of phosphatidyl-
inositol 3-kinase (PI3K) in an indepen-
dent distribution (Hafner et al., 2007d,
2008).
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Figure 1. PTEN (phosphatase and tensin homolog deleted on chromosome 10) hemizygosity is a predisposing factor for skin tumorigenesis following UVA
irradiation. (a) Immunoblot analysis of PTEN protein levels in the epidermis from K14Cre;Ptenþ /þ (þ /þ ) and K14Cre;Ptenfl/þ (þ /) mice. (b) Percentage of
tumor-free mice (n¼ 15). (c) Incidence of seborrheic keratosis (SK) and squamous cell carcinoma (SCC). (d) A mouse with an SK (indicated by a red arrow)
developing in its skin. (e–h) Hematoxylin and eosin staining of the mouse specimens with SK and SCC. (e) SK at  2.5 magnification. (f) SK at original
magnification  10. (g) SCC at original magnification  10. (h) SCC at original magnification 10, with a smaller field of view. (e) Scale bar¼400 mm and
(f–h) scale bar¼100 mm. The green arrow in (h) indicates a multinucleated cell.
Abbreviations: AKT, a serine–threonine kinase, downstream of PI3K, also called protein kinase B; ERK,
extracellular signal-regulated kinase; PI3K, phosphoinositide 3-kinase; PTEN, phosphatase and tensin
homolog deleted on chromosome 10; SCC, squamous cell carcinoma; SK, seborrheic keratosis; þ /þ ,
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SK in UVA-PTEN Interaction in Mice
